{"id":"NCT04391569","sponsor":"Marinus Pharmaceuticals","briefTitle":"Randomized Therapy In Status Epilepticus","officialTitle":"A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in Status Epilepticus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-12-09","primaryCompletion":"2024-03-30","completion":"2024-04-28","firstPosted":"2020-05-18","resultsPosted":"2025-05-29","lastUpdate":"2025-05-29"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Status Epilepticus"],"interventions":[{"type":"DRUG","name":"Ganaxolone","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"IV Placebo","type":"PLACEBO_COMPARATOR"},{"label":"IV ganaxolone active","type":"EXPERIMENTAL"}],"summary":"This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).","primaryOutcome":{"measure":"Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE","timeFrame":"Up to 30 minutes","effectByArm":[{"arm":"Ganaxolone","deltaMin":79.59,"sd":null},{"arm":"Placebo","deltaMin":12.77,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0000"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":74,"countries":["United States","Australia","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":49},"commonTop":["Hypotension","Urinary tract infection","Pyrexia","Hypothermia","Leukocytosis"]}}